ADMA compared with HRTX: revenue, margins and what each company keeps, and the suppliers and customers both name

ADMAAdma Biologics, Inc.

Mkt capRevenueRevenue

HRTXHeron Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ADMAAdma Biologics, Inc.

HRTXHeron Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ADMA

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.7%▲+8.64%×0.74

May 7 '26±14.1%▼−15.97%×1.13

Q1 FY26±10.9%▼−3.19%×0.29

Jan 12 '26±6.8%▼−0.11%×0.01

HRTX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±62.0%▼−31.74%×0.51

May 11 '26±32.7%▼−21.05%×0.65

= impliedADMA realized, solidHRTX realized, hatchedOne scale, both sides: full bar = 63%× = |realized| ÷ impliedSource: market data

Q1 FY26

±34.8%

▲+11.11%

×0.32

Q3 FY25±24.3%▼−3.39%×0.14

ADMAAdma Biologics, Inc.

11.41· pre 11.41· delayed

Mkt cap$2.6BRevenue$124MQ2 FY26Revenue$510MFY25

HRTXHeron Therapeutics, Inc.

0.28· pre 0.28· delayed

Pre-marketOct 30 '26delayed

Mkt cap$52.7MRevenue$38MQ2 FY26Revenue$155MFY25

Compare

Pre-marketOct 30 '26delayed

ADMAAdma Biologics, Inc.

HRTXHeron Therapeutics, Inc.

11.41pre 11.41delayed

Price

0.28pre 0.28delayed

$2.6B

Mkt cap

$52.7M

Q2 FY26$124M

Revenue

$38MQ2 FY26

FY25$510M

Revenue

$155MFY25

ADMA11.41vsHRTX0.28Pre-marketOct 30 '26delayed